



MEMBERSHIP  
June 28, 2023

To whom it may concern,

Company: Japan Lifeline Co. , Ltd.  
Representative: Keisuke Suzuki, President and CEO  
(Code: 7575 TSE Prime Market)  
Contact person: Takeyoshi Egawa, Vice President  
Business Administration Department  
(TEL. +81-3-6711-5200)

**Japan Lifeline Enters into Exclusive Distribution Agreement for VASCADE MVP™,  
A Vascular Closure Device for Femoral Vein**

Japan Lifeline Co., Ltd. has entered into an exclusive distribution agreement with Haemonetics Japan GK for VASCADE MVP™, a vascular closure device for femoral veins used after ablation surgery for atrial fibrillation, on June 28, 2023 in Japan. The product received regulatory approval in April of this year and is scheduled to be launched in the third quarter of the fiscal year ending March 31, 2024.

In atrial fibrillation ablation surgery, the femoral vein is punctured to secure an access route to carry the catheter to the heart, and the puncture site is closed after the procedure is completed. VASCADE MVP™ uses a catheter to deliver a collagen plug into the tissue tract, where the absorbable collagen absorbs tissue fluid and blood, expands, and coagulates to stop bleeding.

The Company will strive to promote the use of VASCADE MVP™ as this product will enable a reduction in hemostasis time, which will benefit both patients and medical professionals.

About Haemonetics Japan GK

Haemonetics Japan GK is a healthcare company dedicated to improving patient care and reducing healthcare costs by providing innovative medical devices and solutions from Haemonetics Corporation. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

Company Name: Haemonetics Japan GK  
Head Office: Tokyo Club Building, 3-2-6, Kasumigaseki, Chiyoda-ku, Tokyo, Japan  
Date of Establishment: August 24, 1983  
URL: <https://www.haemonetics.com/>  
Business activities: Import and sales of medical device